Glucosum

Glucosum is a pharmaceutical product containing glucose as its sole active ingredient. It is supplied in an unspecified strength and dosage form, and is marketed in the European Union. Glucose functions as an energy source and osmotic agent, and Glucosum may be administered via intra‑articular, intravenous, or peri‑articular routes under appropriate clinical supervision. The product is classified as an excipient and is listed under ATC code A12AA01.

Glucosum provides glucose for clinical situations where an immediate source of carbohydrate or osmotic balance is required.

- Intravenous administration to supply energy during surgery or critical care. - Intra‑articular injection as an osmotic agent to aid joint lavage. - Peri‑articular use to support tissue healing after orthopedic procedures. - Diluent or carrier in parenteral nutrition formulations. - Adjunct in diagnostic imaging procedures that require a glucose load.

Glucose administered as Glucosum is generally well tolerated, but adverse reactions can occur.

Common: - Transient hyperglycemia. - Local irritation at the injection site. - Mild nausea or vomiting. - Headache or dizziness.

Serious: - Severe hyperglycemia leading to osmotic diuresis. - Allergic reaction such as urticaria or anaphylaxis. - Electrolyte imbalance, particularly hyponatremia. - Volume overload in patients with cardiac failure.

When using Glucosum, clinicians should evaluate patient-specific factors and monitor for potential complications.

- Assess blood glucose levels before and after administration. - Use caution in patients with diabetes mellitus or impaired glucose tolerance. - Avoid rapid infusion in individuals at risk for fluid overload. - Consider renal or hepatic impairment that may affect glucose metabolism. - Monitor for signs of electrolyte disturbances during prolonged therapy. - Evaluate for hypersensitivity history prior to intra‑articular use.

Glucosum may interact with other agents that influence glucose homeostasis or fluid balance.

Avoid: - Concomitant use of high‑dose insulin or other hypoglycemic agents without dose adjustment. - Co‑administration with large volumes of dextrose‑containing solutions that could cause severe hyperglycemia. - Simultaneous infusion of potassium‑rich solutions in patients prone to hyperkalemia.

Use with caution: - Medications that affect renal function such as NSAIDs or ACE inhibitors. - Drugs that alter electrolyte status, for example loop diuretics. - Anesthetic agents that may mask signs of glucose imbalance.